Neuromeka CEO Jonghoon Park sells 3.68%p stake to fund rights offering, raising dilution and governance concerns

Neuromeka CEO and major shareholder Jonghoon Park reduced his stake from 21.40% to 17.72%, a 3.68 percentage point decrease, through off-hours and OTC sales on July 8, 2026.
The sales involved 80,000 common shares at 32,023 KRW each and 483,612 stock subscription rights at 3,300 KRW each, with the proceeds intended to fund participation in a rights offering.
This reduction in insider ownership raises concerns about management alignment and potential further dilution from the upcoming rights offering, which could pressure the stock price.
[AI Summary]The CEO's substantial stake sale, despite being for rights offering funding, signals reduced skin in the game and adds dilution risk, warranting investor caution.